Navigation Links
Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
Date:9/24/2008

didate is intravenous iclaprim, a potent antibacterial that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The clinical programme for the first indication, complicated skin and skin structure infections (cSSSI), has been completed. The submission of the NDA to the US FDA was completed in March 2008. The FDA has defined that the Prescription Drug User Fee Act (PDUFA) goal date will be 16 January 2009. Arpida submitted a Marketing Authorisation Application for intravenous iclaprim with EMEA in July 2008. EMEA notified that it had accepted the MAA for review in August 2008.

In December 2007, Arpida announced the enrolment of the first patients in a Phase II clinical study with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

In May 2008, Arpida announced the enrolment of the first patients in a Phase II 'intravenous-to-oral' switch trial. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch could be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be effective in eradicating pathogens in preclinical models of skin infection and nasal carriage.

Apart from the antibiotic programmes
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arpida Invited to Present Data on Iclaprim at Scientific Conference
2. Arpida Provides Further Comments on the Pivotal Phase III Trials
3. Arpida Enrols First Patients in "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
10. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
11. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Oct. 1, 2014 NeuroCall, Inc., ... accreditation for its Telestroke and Teleneurology services. Dr. ... NeuroCall, commented, "We are extremely proud that our quality ... as we continue to provide lifesaving support and continuity ... affiliated hospitals throughout the United States ...
(Date:10/1/2014)... , Oct. 1, 2014  Express Scripts (NASDAQ: ... available 2015 Express Scripts Medicare ® Prescription Drug ... featuring Walgreens (NYSE: WAG ) (NASDAQ: ... choice and clinical support  for their Medicare dollars. ... Medicare Value or Choice plans ...
(Date:10/1/2014)... Calif. , Oct. 1, 2014 /PRNewswire/ ... ), a clinical-stage biopharmaceutical company focused on ... positive results from its 371 patient Phase ... with constipation-predominant irritable bowel syndrome (IBS-C).  Results ... clinically meaningful improvement in IBS-C symptoms for ...
Breaking Medicine Technology:NeuroCall Awarded Joint Commission Accreditation 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 3Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6
... , , , RIVIERA BEACH, Fla., Dec. ... for 40 years, announces the launch of the Sigma Elite, ... the Sigma Elite is available on each monoplace chamber model ... , The Sigma Elite New "Smart Hyperbaric System" includes: , ...
... STAMFORD, Conn., Dec. 14 Zargis Medical Corp., a majority-owned ... spin-off from Siemens Corporate Research (NYSE: SI ) ... Cardioscan(TM) system on Amazon.com, America,s largest online retailer. , Cardioscan ... Popular Science magazine,s "2009 Innovation of the ...
Cached Medicine Technology:Perry Baromedical Announces New Cutting Edge Technology With Patient Data Capture Capability 2Zargis Cardioscan 'The Intelligent Stethoscope' Now Available on Amazon.com 2
(Date:10/1/2014)... October 01, 2014 Phoseon Technology, the ... continues to expand the business worldwide. This rapid growth ... additional capacity for manufacturing efforts. The company has experienced ... five years and expects this growth to continue in ... technology gains worldwide adoption. , “We are very ...
(Date:10/1/2014)... Conn. (PRWEB) October 01, 2014 ... company, including a redefined mission and visual identity ... power of partnering with them to create greater ... agile brand that focuses on empowering customers to ... communications. , The crown jewel of the rebrand ...
(Date:10/1/2014)... from Duke Medicine suggests that some people who are ... hard-wired to gain weight when exposed to chronic stress, ... 13 percent of people, all of whom are Caucasian, ... help them reduce heart disease with simple interventions such ... "Genetic susceptibility, psychosocial stress and metabolic factors act in ...
(Date:10/1/2014)... Kennebunkport, Maine (PRWEB) October 01, 2014 ... autoimmune disorders in the U.S., according to figures from ... Autoimmune Related Diseases Association (AARDA), and many of them ... higher chance of having undiagnosed celiac disease. Gluten ... helping raise awareness of undiagnosed celiac disease by publishing ...
(Date:10/1/2014)... 2014 Diet Doc understands that many of ... weight and their dieting attempts could be easily sabotaged by ... hormone diet treatments into their programs as a way ... fast and effective weight loss results, it also allows patients ... to maintain their weight for the future. , Earlier versions ...
Breaking Medicine News(10 mins):Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4
... and District of Columbia get failing grades , , WEDNESDAY, Nov. ... rates, the United States rates a "D," and 18 states ... grades. , That,s the sobering conclusion of the March of ... Wednesday. Not a single state earned an "A." Only one ...
... Bias, Chief Executive Officer of,the National Hemophilia Foundation ... Enterprise magazine in the "On the Move" section ... and women who,have been appointed to new management ... Recent announcements have included leadership posts at,BET, MTV ...
... death (October 18th) Hunter has been,changing the face ... National Spokesperson., CHICAGO, Nov. 12 November ... Foundation (AEOF),joins with Hunter Tylo of CBS,s The ... raise awareness of Epilepsy and educate the public ...
... satisfaction survey shows health improvements, disease ... benefits of plan -, ATLANTA, Nov. 12 One ... 92 percent of members of Care,Improvement Plus feel their health ... satisfaction of the plan,s southeast regional,membership. Of those who feel ...
... vendor of Internet-based diabetes management software MCT-Diabetes, has announced that ... insight and guidance in a regularly scheduled online column to ... ... Acton, MA (PRWEB) November 12, 2008 -- MyCareTeam, Inc., a ...
... Inc. announced today,the launch of MEDVERSATION(TM) ... facilitate more-informed conversations,between U.S. physicians and their ... (infliximab)., This interactive web application, in ... first in its therapeutic class, provides physicians ...
Cached Medicine News:Health News:U.S. Gets a 'D' for Preterm Birth Rates 2Health News:National Hemophilia Foundation's (NHF) CEO Featured in Black Enterprise Magazine 2Health News:November: National Epilepsy Awareness Month Actress Hunter Tylo Turns Tragic Loss Into Hope 2Health News:Georgia and South Carolina Care Improvement Plus Members Overwhelmingly Pleased with Special Needs Plan 2Health News:Nationally Recognized Diabetes Specialist Dr. Steven Edelman to Provide Educational Articles on Diabetes to MyCareTeam's Website Community 2Health News:Nationally Recognized Diabetes Specialist Dr. Steven Edelman to Provide Educational Articles on Diabetes to MyCareTeam's Website Community 3Health News:MEDVERSATION(TM) Website Launched by Centocor to Facilitate Physician-Patient Dialogue About Drug Benefits and Risks 2Health News:MEDVERSATION(TM) Website Launched by Centocor to Facilitate Physician-Patient Dialogue About Drug Benefits and Risks 3Health News:MEDVERSATION(TM) Website Launched by Centocor to Facilitate Physician-Patient Dialogue About Drug Benefits and Risks 4Health News:MEDVERSATION(TM) Website Launched by Centocor to Facilitate Physician-Patient Dialogue About Drug Benefits and Risks 5Health News:MEDVERSATION(TM) Website Launched by Centocor to Facilitate Physician-Patient Dialogue About Drug Benefits and Risks 6
... Sleep Printing Pulse Oximeter ... to address the growing ... that can easily be ... screening for qualifying or ...
Ergonomic design and intuitive operations. Unique DOX digital SpO2 technology improves performance, even under the most challenging clinical conditions....
... The 8600FO is designed ... of MRI users for patient ... Nonin;s Fiber Optic Sensors and ... burns is eliminated, as well ...
The Avant® 9700 combines flexible alarm options, unparalleled non-volatile memory, and Nonins time-honored technology to give you an easy-to-use and efficient monitor....
Medicine Products: